Author

Eric VanCutsem

Observed names: E VanCutsem, E. Vancutsem

Institutions: Universitair Ziekenhuis Leuven, KU Leuven

Observed institutions: Roche (Switzerland), Sunnybrook Health Science Centre, Universitair Ziekenhuis Leuven, Peter MacCallum Cancer Centre, Marqués de Valdecilla University Hospital, Royal Marsden Hospital, KU Leuven

OpenAlex ID: A5080160859

Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC—First B.E.A.Trial

2006 · S. R. Berry, D. Cunningham, et al. · Journal of Clinical Oncology · 44

A Dynamic Model of Hand-and-Foot Syndrome in Patients Receiving Capecitabine

2008 · E Hénin, B You, et al. · Clinical Pharmacology & Therapeutics · 42

Feasibility of metastasectomy in patients treated with bevacizumab in first-line mCRC - Preliminary results from the First Beat-study

2006 · M. Michael, E. Vancutsem, et al. · Journal of Clinical Oncology · 12

Works count: 3

Citation count: 98

H-index: 3

I10-index: 3